California Public Employees Retirement System Acquires 9,000 Shares of Grifols, S.A. (GRFS)

California Public Employees Retirement System grew its holdings in Grifols, S.A. (NASDAQ:GRFS) by 2.2% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 414,700 shares of the biotechnology company’s stock after acquiring an additional 9,000 shares during the quarter. California Public Employees Retirement System’s holdings in Grifols, were worth $8,763,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. ETRADE Capital Management LLC bought a new stake in Grifols, during the second quarter worth about $274,000. FMR LLC raised its stake in Grifols, by 2.7% during the second quarter. FMR LLC now owns 6,523,773 shares of the biotechnology company’s stock worth $137,847,000 after acquiring an additional 171,192 shares in the last quarter. D.A. Davidson & CO. raised its stake in Grifols, by 14.4% during the second quarter. D.A. Davidson & CO. now owns 16,075 shares of the biotechnology company’s stock worth $339,000 after acquiring an additional 2,022 shares in the last quarter. Citigroup Inc. raised its stake in Grifols, by 15.9% during the second quarter. Citigroup Inc. now owns 134,318 shares of the biotechnology company’s stock worth $2,838,000 after acquiring an additional 18,440 shares in the last quarter. Finally, Van ECK Associates Corp raised its stake in Grifols, by 15.4% during the second quarter. Van ECK Associates Corp now owns 820,807 shares of the biotechnology company’s stock worth $17,344,000 after acquiring an additional 109,293 shares in the last quarter. 21.93% of the stock is owned by institutional investors.

Grifols, S.A. (NASDAQ GRFS) opened at 21.185 on Tuesday. The stock has a 50 day moving average price of $20.96 and a 200 day moving average price of $20.76. Grifols, S.A. has a 1-year low of $14.27 and a 1-year high of $22.83. The firm has a market cap of $28.95 billion, a P/E ratio of 43.103 and a beta of 0.98.

WARNING: “California Public Employees Retirement System Acquires 9,000 Shares of Grifols, S.A. (GRFS)” was published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://ledgergazette.com/2017/10/10/california-public-employees-retirement-system-acquires-9000-shares-of-grifols-s-a-grfs.html.

Several research analysts have commented on the company. Goldman Sachs Group, Inc. (The) downgraded Grifols, from a “buy” rating to a “neutral” rating in a research note on Friday, June 30th. BidaskClub downgraded Grifols, from a “hold” rating to a “sell” rating in a research note on Wednesday, July 5th. Bank of America Corporation reaffirmed a “buy” rating on shares of Grifols, in a research note on Tuesday, July 4th. Finally, Zacks Investment Research raised Grifols, from a “hold” rating to a “buy” rating and set a $24.00 price objective for the company in a research note on Tuesday, July 4th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the st

Other institutional investors have also made changes to their positions in the company. ETRADE Capital Management LLC bought a new stake in Grifols, during the second quarter worth about $274,000. FMR LLC raised its stake in Grifols, by 2.7% during the second quarter. FMR LLC now owns 6,523,773 shares of the biotechnology company’s stock worth $137,847,000 after acquiring an additional 171,192 shares in the last quarter. D.A. Davidson & CO. raised its stake in Grifols, by 14.4% during the second quarter. D.A. Davidson & CO. now owns 16,075 shares of the biotechnology company’s stock worth $339,000 after acquiring an additional 2,022 shares in the last quarter. Citigroup Inc. raised its stake in Grifols, by 15.9% during the second quarter. Citigroup Inc. now owns 134,318 shares of the biotechnology company’s stock worth $2,838,000 after acquiring an additional 18,440 shares in the last quarter. Finally, Van ECK Associates Corp raised its stake in Grifols, by 15.4% during the second quarter. Van ECK Associates Corp now owns 820,807 shares of the biotechnology company’s stock worth $17,344,000 after acquiring an additional 109,293 shares in the last quarter. 21.93% of the stock is owned by institutional investors.

Grifols, S.A. (NASDAQ GRFS) opened at 21.185 on Tuesday. The stock has a 50 day moving average price of $20.96 and a 200 day moving average price of $20.76. Grifols, S.A. has a 1-year low of $14.27 and a 1-year high of $22.83. The firm has a market cap of $28.95 billion, a P/E ratio of 43.103 and a beta of 0.98.

WARNING: “California Public Employees Retirement System Acquires 9,000 Shares of Grifols, S.A. (GRFS)” was published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://ledgergazette.com/2017/10/10/california-public-employees-retirement-system-acquires-9000-shares-of-grifols-s-a-grfs.html.

Several research analysts have commented on the company. Goldman Sachs Group, Inc. (The) downgraded Grifols, from a “buy” rating to a “neutral” rating in a research note on Friday, June 30th. BidaskClub downgraded Grifols, from a “hold” rating to a “sell” rating in a research note on Wednesday, July 5th. Bank of America Corporation reaffirmed a “buy” rating on shares of Grifols, in a research note on Tuesday, July 4th. Finally, Zacks Investment Research raised Grifols, from a “hold” rating to a “buy” rating and set a $24.00 price objective for the company in a research note on Tuesday, July 4th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the stock. Grifols, currently has a consensus rating of “Hold” and an average price target of $24.00.

Grifols, Profile

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics.

Want to see what other hedge funds are holding GRFS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Grifols, S.A. (NASDAQ:GRFS).

Institutional Ownership by Quarter for Grifols, (NASDAQ:GRFS)

Receive News & Ratings for Grifols S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols S.A. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply